ABCL FY 2019 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+31.5% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$4M-35.5% margin

Net Income

-$2M-19.0% margin

EPS (Diluted)

$-0.01

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$1M

Stock-Based Comp.

$890,000

Balance Sheet

Total Assets

$23M

Total Liabilities

$13M

Stockholders' Equity

$10M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$9M	+31.5%
Gross Profit	$12M	$9M	+31.5%
Operating Income	-$4M	-$753,000	-446.7%
Net Income	-$2M	$309,000	-815.5%